Indivior Pharmaceuticals, Inc. (INDV)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Indivior Pharmaceuticals, Inc. reported revenue of $1.24B, up 4.3% from the prior year. The company was profitable, with a net margin of 16.9% and a gross margin of 80.2%. It held $1.20B in total assets against $1.30B in total liabilities.
Key ratios (FY2025)
80.2%
Gross margin
21.1%
Operating margin
16.9%
Net margin
+4.3%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $1.24B | $1.19B | $1.09B | $901.00M | — |
| Cost of Revenue | $246.00M | $231.00M | $174.00M | $151.00M | — |
| Gross Profit | $994.00M | $957.00M | $919.00M | $749.00M | — |
| Operating Income | $262.00M | $38.00M | -$152.00M | -$81.00M | — |
| Net Income | $210.00M | $7.00M | -$126.00M | -$44.00M | — |
| EPS (Diluted) | $1.64 | $0.05 | $-0.92 | $-0.32 | — |
| Total Assets | $1.20B | $1.32B | $1.76B | — | — |
| Total Liabilities | $1.30B | $1.65B | $1.94B | — | — |
| Shareholders' Equity | -$98.00M | -$337.00M | -$184.00M | -$15.00M | $121.00M |
| Cash & Equivalents | $195.00M | $319.00M | $316.00M | — | — |
| Operating Cash Flow | -$27.00M | $36.00M | -$300.00M | -$4.00M | — |
| Capital Expenditures | $66.00M | $29.00M | $8.00M | $5.00M | — |
| Shares Outstanding | 128.00M | 133.00M | 137.00M | 139.00M | — |